INVESTIGADORES
CHASSEING Norma Alejandra
artículos
Título:
Post-surgery statin use contributes to favorable outcomes in patients with early breast cancer
Autor/es:
GIORELLO, MARÍA BELÉN; MARKS, MARÍA PAULA; OSINALDE, TIAGO MARTÍN; PADIN, MARÍA DEL ROSARIO; WERNICKE, ALEJANDRA; CALVO, JUAN CARLOS; CHASSEING, NORMA ALEJANDRA; VELLÓN, LUCIANO
Revista:
CANCER EPIDEMIOLOGY
Editorial:
ELSEVIER SCI LTD
Referencias:
Año: 2024 vol. 90
ISSN:
1877-7821
Resumen:
ABSTRACT:Background: Statins are a group of lipid-lowering drugs with pleiotropic effects that include, but are not limited to the inhibition of cholesterol synthesis resulting in a wide range of anti-inflammatory, anti-tumor, immunomodulatory, and anti-thrombotic properties. This study aimed to determine the impact of the prior to- or after breast surgery usage of statins on the tumor prognosis in breast cancer (BC) patients.Methods: A cohort of patients diagnosed with early invasive ductal BC (n=301) at the Hospital Italiano de Buenos Aires, Argentina, with a minimum follow-up period of 10 years after the surgical procedure were included and stratified according to the time of use of statins and type of statin used. Then, local relapse-free survival (RFS), metastasis-free survival (MFS), bone metastasis-free survival (BMFS), visceral metastasis-free (VMFS), mixed metastasis (bone and visceral)-free survival (mix-MFS) and overall survival (OS) were analyzed.Results: Statins usage after breast surgery was related with lesser metastatic occurrence (p=0.017), lower number of metastatic foci (p=0.034) and fewer dead events (p=0.041), as well as longer MFS (p=0.013) and OS (p=0.027). When stratified by the nature of statins (hydrophilic or lipophilic), only the relatively hydrophilic statin rosuvastatin (ROSU) had an impact on the increase of MFS and OS (p=0.018 and p=0.030, respectively).Conclusion: Post-surgery statins usage was associated with increased MFS and OS, with increased benefits of ROSU over simvastatin (SIM) or atorvastatin (ATOR). These results set the rationale for additional studies addressing the use of statins, and particularly, rosuvastatin, to improve the outcome of BC patients.
